Search

Author/Creator Bartz, René

1. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME). Issue 1 (8th November 2019)

Authors:
Bretz, Anne Catherine; Parnitzke, Ulrike; Kronthaler, Kerstin; Dreker, Tobias; Bartz, René; Hermann, Frank; Ammendola, Astrid; Wulff, Tanja; Hamm, Svetlana
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 7:Issue 1(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Phase I study of domatinostat (4SC‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies. (7th January 2019)

Authors:
von Tresckow, Bastian; Sayehli, Cyrus; Aulitzky, Walter E.; Goebeler, Maria‐Elisabeth; Schwab, Matthias; Braz, Eunice; Krauss, Babett; Krauss, Rolf; Hermann, Frank; Bartz, René; Engert, Andreas
Journal:
European journal of haematology
Issue:
Volume 102:Number 2(2019)
Page Start:
163
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC‐202 blocks oncogenic hedgehog‐GLI signaling and overcomes smoothened inhibitor resistance. Issue 5 (6th November 2017)

Authors:
Gruber, Wolfgang; Peer, Elisabeth; Elmer, Dominik P.; Sternberg, Christina; Tesanovic, Suzana; del Burgo, Pedro; Coni, Sonia; Canettieri, Gianluca; Neureiter, Daniel; Bartz, René; Kohlhof, Hella; Vitt, Daniel; Aberger, Fritz
Journal:
International journal of cancer
Issue:
Volume 142:Issue 5(2018)
Page Start:
968
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗